Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 27, 2006
Last updated: November 7, 2013
Last verified: November 2013
This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: GSK159797 (10, 15, and 20mcg)
Drug: salbutamol
Drug: salmeterol 50mcg
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and 20 Mcg) of GSK159797

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Mean change from baseline in trough FEV1 [ Time Frame: after 14 day repeat doses ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean change from baseline in trough FEV1 [ Time Frame: after a single dose ] [ Designated as safety issue: No ]
  • Mean change from baseline in trough FEV1 [ Time Frame: after 7 days repeat dosing ] [ Designated as safety issue: No ]
  • Change from baseline in weighted mean FEV1 0-2 hours, 0-4 hours, 0-24 hours [ Time Frame: Day 1 and Day 14 ] [ Designated as safety issue: No ]

Enrollment: 54
Study Start Date: April 2006
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK159797 (10, 15, and 20mcg)
GSK159797 (10, 15, and 20mcg)
Drug: GSK159797 (10, 15, and 20mcg)
GSK159797 (10, 15, and 20mcg)
Experimental: salbutamol
Drug: salbutamol
Experimental: salmeterol 50mcg
salmeterol 50mcg
Drug: salmeterol 50mcg
salmeterol 50mcg
Placebo Comparator: placebo
Drug: placebo
Other Names:
  • GSK159797 (10
  • 15
  • and 20mcg)
  • salbutamol
  • salmeterol 50mcg


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Subjects with documented history of persistent asthma using corticosteroids at a total daily dose of 200 to 200mcg of FP or equivalent corticosteroid
  • Female subjects only using acceptable birth control method
  • Non-smokers
  • FEV1 between 60 and 90% predicted
  • Increase in FEV1 12% or greater and 300mL and greater after salbutamol use

Exclusion criteria:

  • Past or present disease conditions
  • Normal screening Holter ECG
  • Respiratory tract infection within 4 weeks of screening
  • History of life threatening asthma
  • Previous use of COA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00358488

GSK Investigational Site
Wiesbaden, Hessen, Germany, 65187
GSK Investigational Site
Berlin, Germany, 14057
GSK Investigational Site
Utrecht, Netherlands, 3584 CJ
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 115446
GSK Investigational Site
Lund, Sweden, SE-221 85
United Kingdom
GSK Investigational Site
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00358488     History of Changes
Other Study ID Numbers: B2E106359 
Study First Received: July 27, 2006
Last Updated: November 7, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Federal Institute for Drugs and Medical Devices
Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:
Asthmatic patients

Additional relevant MeSH terms:
Lung Diseases
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 27, 2016